Japan's Medical Distributors FY2026 Full Year: Revenue Hits Record but Costs Bite

Demand continues to expand in the medical distribution sector.
Medipal posted strong net sales of 3.8 trillion yen (up 4% year on year), while Ship Healthcare reached net sales of 718.2 billion yen (up 5.9%).
Although both companies updated their record-high revenues, soaring logistics and labor costs weigh heavily on their bottom lines.
Rising delivery costs driven by driver shortages are the primary culprits.
Aggressive investments for future growth have also led to temporary cost increases.
While healthcare demand remains robust, securing profit margins is becoming increasingly challenging.

A clear contrast emerged in net profit growth.
The winner is Medipal, which managed to secure an increase in net income.
Its net profit reached 42.5 billion yen (up 5.6% year on year) as it successfully captured strong demand for specialty pharmaceuticals.
In contrast, the loser is Ship Healthcare, whose net profit fell to 13.4 billion yen (down 11.5%).
This drop was driven by M&A-related expenses and delays in component deliveries.
However, Ship Healthcare continues to lead in profitability, maintaining an operating margin of 3.4%, which significantly outperforms Medipal at 1.4%.
When it comes to high profit margins, Ship Healthcare still holds a strong advantage.

The two competitors are pursuing different paths to counter rising expenses.
Medipal has moved to make PALTAC a wholly owned subsidiary, aiming to integrate its pharmaceutical and daily goods distribution networks.
This move is designed to maximize delivery efficiency.
On the other hand, Ship Healthcare consolidated five of its subsidiaries to concentrate previously dispersed management resources in the Tokyo metropolitan area.
The company intends to speed up decision-making and streamline sales operations.
Both firms are aiming to scale up while simultaneously driving efficiency.

The overall industry faces three primary structural risks:

• Soaring logistics costs: Delivery fees continue to climb due to acute labor shortages.
• Rising labor expenses: Strategic investments are necessary to recruit and retain high-quality talent.
• Regulatory and policy changes: Profits remain highly sensitive to drug price revisions and the overall financial health of medical institutions.

How these companies absorb these rising overhead costs remains their central challenge.

Supporting the life-saving infrastructure of healthcare, this industry offers exceptional stability as its main appeal.
The sector is currently undergoing a major transformative phase characterized by logistics integration and active M&A.
Joining Medipal offers the chance to experience the dynamism of managing a massive logistics network.
Meanwhile, working at Ship Healthcare provides valuable exposure to diversified portfolio management.
It is an industry that perfectly balances defensive stability with opportunities for new challenges.